Abstract 1711P
Background
The NCCN guidelines recommend that long-acting G-CSF be administered on days 2-4 after chemotherapy to prevent neutropenia. This study investigated the incidence of grade 3/4 neutropenia in patients (pts) with gastrointestinal tumors after administration of mecapegfilgrastim (a long-acting G-CSF) in a real-world setting.
Methods
The prospective, multicenter, non-interventional study analyzed data from pts with gastrointestinal tumors who received mecapegfilgrastim prophylactically at least once. The outcomes including incidence of grade 3/4 neutropenia and febrile neutropenia (FN).
Results
A total of 180 pts with gastrointestinal tumors (74 pts of colorectal cancer, 48 pts of gastric cancer, 40 pts of esophageal cancer and 18 pts of pancreatic cancer) were enrolled in this study. Four hundred and twelve chemotherapy cycles were included for analysis. The median age of pts was 63 years and ECOG PS score was mainly (94%) 0 -1. Fifteen pts (8.3%) had grade ≥3 neutropenia, 3 pts (1.7%) had grade 4 neutropenia. Only one patient (0.5%) had FN. All pts reported adverse event of any grade, 27 pts (15.0%) reported adverse drug reaction. Day 1-Day 14 chemotherapy regimen (D1-14) and Day 1-Day 4 chemotherapy regimen (D1-4) were used in 112 cycles and 251 cycles respectively. In D1-14 regimen cycles, only one cycle (0.9%) had grade ≥3 neutropenia, whereas in D1-4 cycles, 16 cycles (6.4%) had grade ≥3 neutropenia. In the D1-14 regimen cycles, mecapegfilgrastim were administered on day one (31 cycles), day 2 -5 (77 cycles) or after day 5 (4 cycles). Grade ≥3 neutropenia were observed only in one cycle in which mecapegfilgrastim was administered on day 2 - 5. Adverse events and adverse reaction were reported in 50 pts (96.2%) and 4 pts (2.3%) treated with D1-14 regimen.
Conclusions
Mecapegfilgrastim significantly reduced the incidence of neutropenia and FN in pts with gastrointestinal tumors in the real world.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.